Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARQ 621 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARQ 621 treatment | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARQ 621 | DRUG | Treatment will be initiated at a dose level of 10 mg/m\^2 IV infusion for an hour once weekly in 4-week (28 day) consecutive and continuous cycles. ARQ 621 should be infused IV over two hours at doses 200 mg/m\^2 and higher (cohort 8 and above). |
Inclusion Criteria: * Signed written informed consent must be obtained and documented according to International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the local regulatory requirements, and permission to use private health information in accordance with the Health Insuran...
ARQ 621 is an investigational small molecule being studied for the treatment of metastatic solid tumors and refractory or relapsed hematologic malignancies. It is in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being evaluated for safety and efficacy in patients.
ARQ 621 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 1 clinical development for oncology indications.
ARQ 621 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety and potential efficacy in patients with metastatic solid tumors and hematologic malignancies.
ARQ 621 has been studied in one completed clinical trial, identified as NCT00825487. This was a dose escalation study in adult patients with metastatic solid tumors and hematologic malignancies, conducted in the United States with a total enrollment of 50 participants.
ARQ 621 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed clinical trial, NCT00825487, was a dose escalation study, but the drug has not yet received regulatory approval for any indication.